Robert Liptak insider trades: Entasis Therapeutics Holdings (ETTX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
and 5 more companies
Open-market buys and sales
39 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 28, 2018 | ETTX | ↑ Buy | 453,395 | $15.00 | $6.8M | Indirect | Oct 2, 2018 (4d) |
| Jul 2, 2018 | FTSV | ↑ Buy | 200,000 | $16.00 | $3.2M | Indirect | Jul 2, 2018 (0d) |
| Feb 9, 2016 | TLOG | ↓ Sell | 333,630 | $0.17 | $56K | Direct | Feb 10, 2016 (1d) |
| Feb 5, 2016 | TLOG | ↓ Sell | 1,415,490 | $0.18 | $249K | Direct | Feb 5, 2016 (0d) |
| Feb 2, 2016 | TLOG | ↓ Sell | 369,132 | $0.19 | $72K | Direct | Feb 2, 2016 (0d) |
| Jan 28, 2016 | TLOG | ↓ Sell | 311,930 | $0.28 | $86K | Direct | Jan 28, 2016 (0d) |
| Jan 6, 2016 | GMED | ↓ Sell | 15,300 | $27.50 | $421K | Direct | Jan 6, 2016 (0d) |
| Jun 16, 2015 | OXFD | ↓ Sell | 41,230 | $14.30 | $590K | Direct | Jun 17, 2015 (1d) |
| Jun 12, 2015 | OXFD | ↓ Sell | 31,598 | $14.27 | $451K | Direct | Jun 12, 2015 (0d) |
| Jun 10, 2015 | OXFD | ↓ Sell | 24,649 | $14.28 | $352K | Direct | Jun 10, 2015 (0d) |
| Jun 3, 2015 | OXFD | ↓ Sell | 36,474 | $14.29 | $521K | Direct | Jun 3, 2015 (0d) |
| Mar 23, 2015 | OXFD | ↓ Sell | 53,415 | $14.49 | $774K | Direct | Mar 24, 2015 (1d) |
| Mar 19, 2015 | OXFD | ↓ Sell | 154,319 | $14.65 | $2.3M | Direct | Mar 19, 2015 (0d) |
| Jan 8, 2015 | AERI | ↓ Sell | 175,000 | $31.11 | $5.4M | Direct | Jan 12, 2015 (4d) |
| Jan 5, 2015 | AERI | ↓ Sell | 23,620 | $30.86 | $729K | Direct | Jan 6, 2015 (1d) |
| Dec 29, 2014 | AERI | ↓ Sell | 80,724 | $30.05 | $2.4M | Direct | Dec 30, 2014 (1d) |
| Dec 23, 2014 | AERI | ↓ Sell | 49,704 | $30.36 | $1.5M | Direct | Dec 24, 2014 (1d) |
| Jun 11, 2014 | OPHT | ↓ Sell | 211,180 | $45.42 | $9.6M | Direct | Jun 11, 2014 (0d) |
| Jun 11, 2014 | OPHT | ↓ Sell | 500 | $44.32 | $22K | Indirect | Jun 11, 2014 (0d) |
| Dec 17, 2013 | TLOG | ↑ Buy | 1,425,063 | $7.00 | $10.0M | Direct | Dec 19, 2013 (2d) |
| Dec 6, 2013 | GMED | ↓ Sell | 25,000 | $19.36 | $484K | Direct | Dec 10, 2013 (4d) |
| Oct 25, 2013 | AERI | ↑ Buy | 321,000 | $10.00 | $3.2M | Direct | Oct 28, 2013 (3d) |
| Aug 8, 2012 | GMED | ↓ Sell | 804,232 | $11.16 | $9.0M | By L.P. | Aug 10, 2012 (2d) |
| Aug 8, 2012 | GMED | ↓ Sell | 804,232 | $11.16 | $9.0M | By Fund | Aug 10, 2012 (2d) |
| May 31, 2012 | ACHN | ↓ Sell | 1,316,956 | $7.49 | $9.9M | By Fund | Jun 4, 2012 (4d) |
| Sep 16, 2011 | ZGNX | ↑ Buy | 3,500,000 | $2.00 | $7.0M | By Fund | Sep 20, 2011 (4d) |
| Nov 29, 2010 | ZGNX | ↑ Buy | 1,750,000 | $4.00 | $7.0M | Direct | Nov 30, 2010 (1d) |
| Nov 9, 2010 | AVNR | ↓ Sell | 1,244,626 | $4.82 | $6.0M | By Fund | Nov 10, 2010 (1d) |
| Nov 5, 2010 | AVNR | ↓ Sell | 1,732,678 | $4.58 | $7.9M | By Fund | Nov 5, 2010 (0d) |
| Nov 2, 2010 | AVNR | ↓ Sell | 5,193,960 | $5.06 | $26.3M | By Fund | Nov 2, 2010 (0d) |
| Oct 11, 2010 | AVNR | ↓ Sell | 551,838 | $3.50 | $1.9M | By Fund | Oct 12, 2010 (1d) |
| Aug 20, 2010 | ACHN | ↑ Buy | 4,875,502 | $2.49 | $12.1M | By Fund | Aug 20, 2010 (0d) |
| Jul 13, 2010 | AVNR | ↓ Sell | 165,000 | $3.53 | $583K | By Fund | Jul 15, 2010 (2d) |
| Jan 11, 2010 | ACHN | ↓ Sell | 233,990 | $3.77 | $881K | By Fund | Jan 13, 2010 (2d) |
| Jan 7, 2010 | ACHN | ↓ Sell | 53,000 | $3.50 | $186K | By Fund | Jan 8, 2010 (1d) |
| Dec 24, 2009 | ACHN | ↓ Sell | 3,600 | $3.53 | $13K | By Fund | Dec 29, 2009 (5d) |
| Dec 23, 2009 | ACHN | ↓ Sell | 284,000 | $3.69 | $1.0M | By Fund | Dec 23, 2009 (0d) |
| Dec 18, 2009 | ACHN | ↓ Sell | 207,176 | $3.53 | $730K | By Fund | Dec 18, 2009 (0d) |
| Sep 8, 2008 | ACHN | ↑ Buy | 4,654 | $2.25 | $10K | By Fund | Sep 9, 2008 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Robert Liptak's insider trades
Robert Liptak is a 10% owner of Entasis Therapeutics Holdings (ETTX). Since Sep 8, 2008, Robert has reported 8 open-market purchases worth $49.3M and 31 sales worth $99.5M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include conversions (10 filings), grants and awards (9 filings), other transactions (8 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ETTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.